← Every company
AbbVie Inc Patents
What AbbVie Inc has filed at the patent office — applications as well as grants, because a filing is on the record eighteen months before anyone has to say what it was for.
ABBV on carbonthat →Filings on file
59
Granted
4
Still pending
55
Filed under
9 names
59 filings
Newest filing first. A pending application has no patent number yet, and most never get one.
| Invention | Patent |
|---|---|
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFC07D 487/14, A61K 9/0053, A61K 31/4985, A61K 47/12, A61K 47/38, C07B2200/13Filed as AbbVie Inc.2026-06-10Ayman Allian | pending |
| RISANKIZUMAB COMPOSITIONSA61K 9/0019, C07K 16/244, A61K 9/08, A61K 38/465, A61K 39/3955, A61K 39/39591, A61K 47/10, A61K 47/12, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/14, C07K2317/24, C07K2317/41, C07K2317/524, C07K2317/71, C07K2317/76, C12Y 301/01004, G01N 33/573, G01N2333/918Filed as ABBVIE INC.2026-05-19Chen WANG | pending |
| RISANKIZUMAB COMPOSITIONSA61K 9/0019, C07K 16/244, A61K 9/08, A61K 38/465, A61K 39/3955, A61K 39/39591, A61K 47/10, A61K 47/12, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/14, C07K2317/24, C07K2317/41, C07K2317/524, C07K2317/71, C07K2317/76, C12Y 301/01004, G01N 33/573, G01N2333/918Filed as ABBVIE INC.2026-05-18Chen WANG | pending |
| RISANKIZUMAB COMPOSITIONSA61K 9/0019, C07K 16/244, A61K 9/08, A61K 38/465, A61K 39/3955, A61K 39/39591, A61K 47/10, A61K 47/12, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/14, C07K2317/24, C07K2317/41, C07K2317/524, C07K2317/71, C07K2317/76, C12Y 301/01004, G01N 33/573, G01N2333/918Filed as ABBVIE INC.2026-05-15Chen WANG | pending |
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZ0[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFA61K 31/4985, C07D 487/14, A61K 9/0053, A61K 9/08, A61K 9/2054, A61K 9/4858, A61K 31/519, A61K 47/02, A61K 47/12, A61K 47/38, C07B2200/13, C07D 487/04Filed as AbbVie Inc.2026-04-30Ayman Allian | pending |
| METHODS OF TREATING VITILIGO WITH UPADACITINIBA61K 31/4985, A61P 37/00, A61P 17/00, A61K 9/0053, A61K 9/08, A61K 47/12Filed as AbbVie Inc.2026-04-17Sumit Bhatnagar | pending |
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFC07D 487/14, A61K 9/0053, A61K 31/4985, A61K 47/02, A61K 47/12, A61K 47/38, C04B 35/62873, C04B 35/62886, C04B 35/64, C04B 35/657, C04B 35/83, C04B2235/422, C04B2235/48, C04B2235/5248, C04B2235/5256, C04B2235/616, C07B2200/13, C07D 487/04Filed as AbbVie Inc.2026-03-13Ayman Allian | pending |
| FOLATE RECEPTOR ALPHA ANTIBODY DRUG CONJUGATESA61K 47/6803, A61K 47/68037, A61K 47/6849, A61K 47/6875, A61P 35/00, C07K 16/28, C07K2317/33, C07K2317/35, C07K2317/92Filed as AbbVie Inc.2026-03-12Susan E. Morgan-Lappe | pending |
| FOLATE RECEPTOR ALPHA ANTIBODY DRUG CONJUGATESFiled as ABBVIE INC.2026-03-12SUSAN E. MORGAN-LAPPE | pending |
| METHODS OF TREATING PEDIATRIC PATIENTS WITH UPADACITINIBA61K 31/4985, A61P 17/06, A61P 37/02, A61P 17/00, A61P 19/02, A61P 1/00, A61K 9/0095, A61K 47/12, A61K 47/32Filed as AbbVie Inc.2026-02-27Mohamed-Eslam F. Mohamed | pending |
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFFiled as AbbVie Inc.2026-02-06Ayman Allian | pending |
| Methods of Administering ElagolixA61K 31/137, A61K 31/513, A61K 9/0053, A61K 31/4439, A61K 31/565, A61K 31/57, A61K2300/00Filed as AbbVie Inc.2025-12-18Farah N. Ali | pending |
| ANTI-GPC3 ANTIBODY DRUG CONJUGATESFiled as ABBVIE INC.2025-12-17EMILY JEAN FAIVRE | pending |
| METHODS OF ADMINISTERING ELAGOLIXA61K 31/505, A61P 15/00, A61K 9/0053, A61K 31/4178, A61K 31/496, A61K 31/513, A61K 31/565, A61K 31/567, A61K2300/00Filed as AbbVie Inc.2025-12-12Sandra L. Goss | pending |
| METHODS OF USING ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSISC07K 16/28, A61P 7/06, A61P 7/00, A61P 35/00, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/24, C07K2317/33, C07K2317/34, C07K2317/524, C07K2317/526, C07K2317/565, C07K2317/71, C07K2317/72, C07K2317/76, C07K2317/90, C07K2317/92Filed as AbbVie Deutschland GmbH & Co. KG2025-11-24Maria Beconi | 12715917 |
| Methods of Treatment Using Anti-C-Met Antibody Drug ConjugatesA61K 47/6849, A61K 47/6889, A61P 35/00, A61K 47/68037Filed as AbbVie Manufacturing Management Unlimited Company2025-11-21Xiaowen Guan | pending |
| CLOSTRIDIUM BOTULINUM SEROTYPE A NEUROTOXIN (BONT/A) SEQUENCE VARIANTSA61K 38/164, A61K 38/4893, C07K 14/33, C12N 15/11, A61P 21/00, Y02A 50/30, C12R2001/145, A61K 9/1611, A61K 39/08, A61K 47/42, C12M 35/08, C12N 1/20, C12N 9/52, C12N2500/02, C12N2500/92, C12P 21/02, C12Y 304/24069Filed as AbbVie Inc.2025-11-12Robert R. KEHRER | pending |
| ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSISC07K 16/28, A61P 7/06, A61P 7/00, A61P 35/00, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/24, C07K2317/33, C07K2317/34, C07K2317/524, C07K2317/526, C07K2317/565, C07K2317/71, C07K2317/72, C07K2317/76, C07K2317/90, C07K2317/92Filed as AbbVie Deutschland GmbH & Co. KG2025-11-03Maria Beconi | 12715916 |
| SUBCUTANEOUSLY ADMINISTERED TREATMENTS FOR ADVANCED PARKINSON’S DISEASEA61K 31/661, A61P 25/28, A61P 25/16, A61K 9/0019, A61K2300/00Filed as AbbVie Inc.2025-10-29Maurizio Facheris | pending |
| ANTI-C-MET ANTIBODY DRUG CONJUGATESA61K 47/6857, C07D 491/22, C07K 16/2863, A61K 47/6803, A61K 47/6849, A61P 35/00, A61K 47/68037, A61K2039/505, C07K 5/06043, C07K 5/06086, C07K 5/0817, C07K2317/565, C07K2317/73, C07K2317/92Filed as ABBVIE MANUFACTURING MANAGEMENT UNLIMITED COMPANY2025-10-03Andrew C. Phillips | pending |
| Levodopa and Carbidopa Intestinal Gel and Methods of UseA61K 31/198, A61P 25/16, A61K 9/00, A61K 9/0053, A61K 9/10, A61K 31/195, A61K 47/10, A61K 47/32, A61K 47/38, A61K2300/00Filed as AbbVie Inc.2025-09-19Alexandru DEAC | pending |
| EXTENDED RELEASE UPADACITINIB FORMULATIONSA61K 9/205, A61K 9/2054, A61K 31/4985, A61P 19/02, A61P 29/00, A61K 9/0004, A61K 9/0053, A61K 9/2009, A61K 9/2013, A61K 9/2018, A61K 9/2031, A61K 9/2072, A61K 9/2086, A61K 9/2853, A61K 9/286, A61K 9/2866Filed as ABBVIE INC.2025-09-09Yihong QIU | pending |
| METHODS OF TREATING VITILIGO WITH UPADACITINIBFiled as AbbVie Inc.2025-08-29Sumit Bhatnagar | pending |
| Dosing Regimens for ElagolixA61P 15/00, A61K 31/513, A61P 19/00, A61P 5/02, A61K 31/565, A61K 31/567, A61K 45/06, C07D 239/54, A61K2300/00Filed as AbbVie Inc.2025-08-26Mohamad Shebley | pending |
| Methods of Treating Heavy Menstrual BleedingA61K 31/513, A61K 31/57, A61P 15/00, A61K 31/565, A61K 31/567, A61K 45/06, A61K2300/00Filed as AbbVie Inc.2025-08-15Kristof Chwalisz | pending |
| ANTIBODY-DRUG CONJUGATES COMPRISING TRABECTEDIN AND LURBINECTEDIN DERIVATIVESFiled as AbbVie Group Holdings Limited2025-08-15Bin ZOU | pending |
| Anti-Sars-COV-2 Antibodies and Uses ThereofA61P 31/14, C07K 16/104, C07K2317/21, C07K2317/34, C07K2317/565, C07K2317/76, C07K2317/92Filed as AbbVie Inc.2025-07-30Danyal Butt | pending |
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFFiled as AbbVie Inc.2025-07-29Ayman Allian | pending |
| DEVICES AND METHODS FOR DELIVERING A BENEFICIAL AGENT TO A USERA61M 5/16804, A61J 1/10, A61M 5/14228, A61M 5/14232, A61M 5/162, A61M2205/123Filed as ABBVIE INC.2025-07-25Ted HANAGAN | pending |
| CLOSTRIDIUM BOTULINUM SEROTYPE A NEUROTOXIN (BONT/A) SEQUENCE VARIANTSA61K 38/164, A61K 38/4893, C07K 14/33, C12N 15/11, A61P 21/00, Y02A 50/30, C12R2001/145, A61K 9/1611, A61K 39/08, A61K 47/42, C12M 35/08, C12N 1/20, C12N 9/52, C12N2500/02, C12N2500/92, C12P 21/02, C12Y 304/24069Filed as AbbVie Inc.2025-07-18Robert R. KEHRER | pending |
| CLOSTRIDIUM BOTULINUM NEUROTOXIN SEROTYPE A COMPOSITIONSA61K 38/164, A61K 38/4893, C07K 14/33, C12N 15/11, A61P 21/00, Y02A 50/30, C12R2001/145, A61K 39/08, C12N 1/20, C12N 9/52, C12N2500/92, C12N2523/00, C12Y 304/24069Filed as AbbVie Inc.2025-07-18Robert R. KEHRER | pending |
| Bromodomain InhibitorsA61K 31/407, C07D 471/04, A61P 27/02, A61P 17/06, A61P 21/00, A61P 9/10, A61P 19/00, A61P 19/06, A61P 25/28, A61P 1/16, A61P 3/00, A61P 9/00, A61P 11/06, A61P 37/06, A61P 1/18, A61P 3/04, A61P 3/06, A61P 15/16, A61P 17/00, A61P 19/02, A61P 31/18, A61P 35/02, A61P 3/10, A61P 13/12, A61P 31/04, A61P 11/00, A61P 25/00, A61P 29/00, A61P 1/04, A61P 17/04, A61P 35/00, A61K 31/437, A61K 31/444, C07D 487/04Filed as AbbVie Inc.2025-07-17Steven D. Fidanze | pending |
| METHODS OF TREATING PEDIATRIC PATIENTS WITH UPADACITINIBFiled as AbbVie Inc.2025-07-11Mohamed-Eslam F. Mohamed | pending |
| METHODS OF TREATING HIDRADENITIS SUPPURATIVAA61P 17/10, C07K 16/245, A61P 17/00, A61P 29/00, A61K 9/0019, A61K 38/00, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/31, C07K2317/60, C07K2317/64, C07K2317/76Filed as AbbVie Deutschland GmbH & Co. KG2025-07-11Mona Akbari | pending |
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-e]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFFiled as AbbVie Inc.2025-07-06Ayman Allian | pending |
| 1,3,4,7-TETRAHYDRO-2H-PYRROLO[3',2':5,6]PYRIDO[2,3-B][1,4]OXAZEPINE BCL-2 INHIBITORSA61P 35/02, C07D 498/14, C07D 519/00, A61K 31/553Filed as AbbVie Inc.2025-07-02George A. Doherty | pending |
| ANTI-CD79B ANTIBODY DRUG CONJUGATESFiled as ABBVIE INC.2025-06-24DAVID GREGORY BELAIR | pending |
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFFiled as AbbVie Inc.2025-06-20Ayman Allian | pending |
| ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSISC07K 16/28, A61P 7/06, A61P 7/00, A61P 35/00, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/24, C07K2317/33, C07K2317/34, C07K2317/524, C07K2317/526, C07K2317/565, C07K2317/71, C07K2317/72, C07K2317/76, C07K2317/90, C07K2317/92Filed as AbbVie Deutschland GmbH & Co. KG2025-06-06Maria Beconi | pending |
| ANTI-HEMOJUVELIN (HJV) ANTIBODIES FOR TREATING MYELOFIBROSISC07K 16/28, A61P 7/06, A61P 7/00, A61P 35/00, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/24, C07K2317/33, C07K2317/34, C07K2317/524, C07K2317/526, C07K2317/565, C07K2317/71, C07K2317/72, C07K2317/76, C07K2317/90, C07K2317/92Filed as AbbVie Deutschland GmbH & Co. KG2025-06-05Maria Beconi | 12497452 |
| ENZYME COMPOSITIONS WITH REDUCED VIRAL AND MICROBIAL CONTAMINATIONA61K 38/54, A61K 41/10, A61K 38/465, A61L 2/08, C12N 9/20, C12N 9/94, C12N 13/00, C12Y 301/01003Filed as AbbVie Inc.2025-05-23Martin Babcock | pending |
| TARGETED PROTEIN DEGRADATION OF PARP14 FOR USE IN THERAPYC07D 401/14, C07D 403/14, C07K 5/021, A61P 35/02, A61P 29/00, A61P 35/00, A61K 31/517, C07D 405/14, C07D 417/14Filed as AbbVie Biotechnology Ltd2025-05-22Laurie B. Schenkel | pending |
| WEARABLE AUTOMATIC INJECTION SYSTEM AND APPARATUSA61M 5/19, A61M 5/2066, A61M 5/206, A61M 5/14244, A61M 5/14248, A61M 5/2448, A61M2205/3606Filed as Abbvie Inc.2025-05-22Wolfgang Fraunhofer | pending |
| TREATING SPONDYLOARTHRITIC AND PSORIATIC CONDITIONS WITH UPADACITINIBA61K 31/4985, A61P 17/06, A61P 19/02, A61P 19/08, A61K 9/0053, A61K 45/06Filed as AbbVie Inc.2025-05-19Aileen L. Pangan | pending |
| TIPARP INHIBITOR COMPOUNDSFiled as ABBVIE INC.2025-04-25WEN-JU BAI | pending |
| RISANKIZUMAB COMPOSITIONSA61K 9/0019, C07K 16/244, A61K 9/08, A61K 38/465, A61K 39/3955, A61K 39/39591, A61K 47/10, A61K 47/12, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/14, C07K2317/24, C07K2317/41, C07K2317/524, C07K2317/71, C07K2317/76, C12Y 301/01004, G01N 33/573, G01N2333/918Filed as ABBVIE INC.2025-04-25Liqiang Zhou | pending |
| Tiparp Inhibitor CompoundsC07D 401/14, A61P 35/00, A61K 31/506Filed as AbbVie Inc.2025-04-24Wen-Ju Bai | pending |
| RISANKIZUMAB COMPOSITIONSA61K 9/0019, C07K 16/244, A61K 9/08, A61K 38/465, A61K 39/3955, A61K 39/39591, A61K 47/10, A61K 47/12, A61K 47/26, A61K2039/505, A61K2039/54, A61K2039/545, C07K2317/14, C07K2317/24, C07K2317/41, C07K2317/524, C07K2317/71, C07K2317/76, C12Y 301/01004, G01N 33/573, G01N2333/918Filed as ABBVIE INC.2025-04-24Chen WANG | pending |
| METHODS OF TREATMENT USING ANTI-SEZ6 ANTIBODY DRUG CONJUGATESA61K 47/68037, A61K 47/6889, A61K 47/6857, A61K 47/6849, A61P 35/00, A61K2039/505, A61K2039/545, C07K 16/18, C07K 16/28, A61K 39/39558, A61K2300/00Filed as AbbVie Inc.2025-04-21Randy R. Robinson | pending |
| METHODS OF TREATMENT USING ANTI-SEZ6 ANTIBODY DRUG CONJUGATESFiled as ABBVIE INC.2025-04-21RANDY R. ROBINSON | pending |
| LPAR1 InhibitorsA61P 19/00, A61K 31/454, C07D 401/04, A61P 37/00, A61P 17/00, A61P 29/00, A61K 31/4545, A61K 31/5377, C07D 401/14, C07D 405/14, C07D 407/14, C07D 409/14, C07D 413/14, C07D 417/14, C07D 491/048, C07D 493/04Filed as AbbVie Inc.2025-04-18Henry Korman | pending |
| LPAR1 INHIBITORSFiled as ABBVIE INC.2025-04-17HENRY KORMAN | pending |
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFC07D 487/14, A61K 9/0053, A61K 9/20, A61K 9/48, A61K 31/4985, A61K 47/02, A61K 47/12, A61K 47/38, C07B2200/13, C07D 487/04Filed as AbbVie Inc.2025-04-17Mohamed-Eslam F. Mohamed | 12570664 |
| METHOD OF TREATING GIANT CELL ARTERITIS WITH UPADACITINIBFiled as ABBVIE INC.2025-04-15AILEEN L. PANGAN | pending |
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFC07D 487/14, A61P 7/00, A61P 17/06, A61P 37/02, A61P 43/00, A61P 17/14, A61P 17/00, A61P 19/02, A61P 37/08, A61P 29/00, A61P 1/04, A61P 35/00, A61K 9/0053, A61K 31/4985, A61K 47/02, A61K 47/12, A61K 47/38, C04B 35/62873, C04B 35/62886, C04B 35/64, C04B 35/657, C04B 35/83, C04B2235/422, C04B2235/48, C04B2235/5248, C04B2235/5256, C04B2235/616, C07B2200/13, C07D 487/04Filed as AbbVie Inc.2025-04-15Ayman Allian | pending |
| PROCESSES FOR THE PREPARATION OF (3S,4R)-3-ETHYL-4-(3H-IMIDAZO[1,2-a]PYRROLO[2,3-e]-PYRAZIN-8-YL)-N-(2,2,2-TRIFLUOROETHYL)PYRROLIDINE-1-CARBOXAMIDE AND SOLID STATE FORMS THEREOFC04B 35/83, C04B 35/62873, C04B 35/62886, C04B 35/64, C04B 35/657, C04B2235/422, C04B2235/48, C04B2235/5248, C04B2235/5256, C04B2235/616Filed as AbbVie Inc.2025-04-09Ayman Allian | pending |
| TREATMENT OF OCULAR DISEASES WITH RECOMBINANT VIRAL VECTORS ENCODING ANTI-VEGF FABA61K 39/3955, A61K 48/0075, C07K 16/22, A61P 27/02, A61P 9/10, A61F 9/0008, A61K 9/0048, A61K 31/573, A61K 31/575, A61K 31/58, A61K 45/06, A61K 48/0066, A61K2039/505, A61K2039/545, A61K2300/00, C12N 15/86, C12N 15/864, C12N2750/14143Filed as ABBVIE GLOBAL ENTERPRISES LTD.2025-03-28Sherri VAN EVEREN | pending |
| ANTI-ALPHA-4-BETA-7 ANTIBODIESC07K 16/2839, A61P 31/18, A61K2039/505, C07K2317/52, C07K2317/565, C07K2317/732, C07K2317/734, C07K2317/76, C12N 15/63Filed as AbbVie Inc.2025-03-19Jing Min | pending |
| BISPECIFIC BINDING MOLECULESC07K 16/2809, C07K 14/7051, C07K 16/18, C07K2317/31, C07K2317/55, C07K2317/90, C07K2319/30, C07K 16/30, C07K2317/522, C07K2317/524, C07K2317/526, C07K2317/74, C07K2317/92, C07K2317/94, C07K2319/00Filed as AbbVie Inc.2025-03-19Adam Chervin | pending |
Filings are matched to the company by applicant name, so a subsidiary filing under its own name is only here if that name resolves to this company. The applicant is printed as filed, which makes a wrong match visible. A patent is not a product: most applications are never granted, and most grants are never built.
More on ABBV
Company overviewEverything on ABBV in one place, with the price.SEC filingsWhat ABBV's 8-Ks say happened: results, departures, auditor changes.Insider tradingWhat ABBV's own officers and directors buy and sell.Who owns itEvery manager reporting a position in ABBV.Funds holding itWhich funds and ETFs hold ABBV, and how big a bet.LobbyingWhat ABBV spends lobbying Congress, and on what.Who lobbies for itThe lobbyists on ABBV's account, and who they worked for.Federal contractsWhat federal agencies pay ABBV.Workplace safetyWhat OSHA found at ABBV's sites.